AstraZeneca's Interest in Rhythm Pharmaceuticals Looks Sensible

Dow Jones11-05

1205 GMT - AstraZeneca's interest in acquiring Rhythm Pharmaceuticals shouldn't come as a surprise, as it would represent a replay--at a smaller scale--of its purchase of Alexion, Jefferies analysts say. The Wall Street Journal reported on Wednesday that AstraZeneca made a roughly $10 billion offer to buy Rhythm. "Where this approach got to is unclear, but in essence looking for rare disease assets that fit [AstraZeneca's] existing footprint is entirely sensible in our view," Jefferies says. The U.K. drugmaker doesn't need external help to reach its $80 billion 2030 revenue target, but adding assets that offer growth potential isn't a bad idea, the analysts say. AstraZeneca shares rise 0.2%, and Rhythm closed 28% higher on Wednesday.

 

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment